A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
Status:
Completed
Trial end date:
2020-01-08
Target enrollment:
Participant gender:
Summary
To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL
administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis
either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject
self-administration with autoinjector/pen (AI/Pen)